| Firm |
Analyst |
| Auriga USA
|
Difei Yang |
| Bank of America/Merrill Lynch
|
Rachel McMinn |
| Caris & Company
|
Mario Corso |
| Cowen & Company
|
Phil Nadeau |
| Goldman Sachs
|
Terence Flynn |
| Jefferies & Company
|
Thomas Wei |
| JMP Securities
|
Liisa Bayko |
| JP Morgan
|
Geoffrey Meacham |
| Lazard Capital Markets
|
Brian Klein |
| Leerink Swann
|
Joseph Schwartz |
| Maxim Group
|
Yale Jen |
| Oppenheimer
|
Chris Holterhoff |
| Piper Jaffray
|
Ted Tenthoff |
| Stifel Nicolaus
|
Stephen Willey |
| WBB Securities
|
Steven Brozak |
| WJB Capital Group
|
John Newman |
ViroPharma Incorporated is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding ViroPharma Incorporated's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ViroPharma Incorporated or its management. ViroPharma Incorporated does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
|